Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 2
2012 1
2013 1
2014 3
2015 5
2017 1
2018 2
2019 2
2020 1
2021 1
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Fragment-Based Discovery of Pyrimido[1,2-b]indazole PDE10A Inhibitors.
Chino A, Seo R, Amano Y, Namatame I, Hamaguchi W, Honbou K, Mihara T, Yamazaki M, Tomishima M, Masuda N. Chino A, et al. Among authors: amano y. Chem Pharm Bull (Tokyo). 2018;66(3):286-294. doi: 10.1248/cpb.c17-00836. Chem Pharm Bull (Tokyo). 2018. PMID: 29491261 Free article.
Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity.
Imaizumi T, Akaiwa M, Abe T, Nigawara T, Koike T, Satake Y, Watanabe K, Kaneko O, Amano Y, Mori K, Yamanaka Y, Nagashima T, Shimazaki M, Kuramoto K. Imaizumi T, et al. Among authors: amano y. Bioorg Med Chem. 2022 Oct 1;71:116949. doi: 10.1016/j.bmc.2022.116949. Epub 2022 Jul 30. Bioorg Med Chem. 2022. PMID: 35926326
Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency.
Kuriwaki I, Kameda M, Iikubo K, Hisamichi H, Kawamoto Y, Kikuchi S, Moritomo H, Kondoh Y, Terasaka T, Amano Y, Tateishi Y, Echizen Y, Iwai Y, Noda A, Tomiyama H, Nakazawa T, Hirano M. Kuriwaki I, et al. Among authors: amano y. Bioorg Med Chem. 2021 Mar 1;33:116019. doi: 10.1016/j.bmc.2021.116019. Epub 2021 Jan 16. Bioorg Med Chem. 2021. PMID: 33486159
Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2.
Kuriwaki I, Kameda M, Hisamichi H, Kikuchi S, Iikubo K, Kawamoto Y, Moritomo H, Kondoh Y, Amano Y, Tateishi Y, Echizen Y, Iwai Y, Noda A, Tomiyama H, Suzuki T, Hirano M. Kuriwaki I, et al. Among authors: amano y. Bioorg Med Chem. 2020 May 15;28(10):115453. doi: 10.1016/j.bmc.2020.115453. Epub 2020 Mar 28. Bioorg Med Chem. 2020. PMID: 32278710
Discovery of a Hidden Trypanosoma cruzi Spermidine Synthase Binding Site and Inhibitors through In Silico, In Vitro, and X-ray Crystallography.
Yoshino R, Yasuo N, Hagiwara Y, Ishida T, Inaoka DK, Amano Y, Tateishi Y, Ohno K, Namatame I, Niimi T, Orita M, Kita K, Akiyama Y, Sekijima M. Yoshino R, et al. Among authors: amano y. ACS Omega. 2023 Jul 12;8(29):25850-25860. doi: 10.1021/acsomega.3c01314. eCollection 2023 Jul 25. ACS Omega. 2023. PMID: 37521650 Free PMC article.
Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors.
Imaizumi T, Shimada I, Satake Y, Yamaki S, Koike T, Nigawara T, Kaneko O, Amano Y, Mori K, Yamanaka Y, Nakayama A, Nishizono Y, Shimazaki M, Nagashima T, Kuramoto K. Imaizumi T, et al. Among authors: amano y. Bioorg Med Chem. 2024 Jan 15;98:117581. doi: 10.1016/j.bmc.2023.117581. Epub 2023 Dec 27. Bioorg Med Chem. 2024. PMID: 38176113
22 results